Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.40 -0.17%

-$0.01 today

Market cap
$289.58M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.88M

Average 0.82M

AGEN Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Agenus Inc.NASDAQ: AGEN

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity remains negative

Q1 FY2026 total equity was -$227.98M, compared with -$322.4M a year earlier.

Context

  • Total equity amounted to 122.3% of total assets at the end of Q1 FY2026, down 38.8 pp from a year earlier.
  • Total equity grew in size in 2 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +29.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$227.98M+18.0% QoQ
Last fiscal yearDec 2025
-$277.86M+9.3% YoY
Year agoMar 2025
-$322.4M+29.3% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.3%——
1 year+9.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
(277.86M) USD
Year-over-year change
+9.3%

Total Equity vs competitors

How AGEN compares with its peers on the latest reported figures

  • AGEN's Mar 2026 total equity of -$227.98M is the lowest of the 10 companies compared; the peer median is $87.48M.
  • Its year-over-year change of +29.3% is the 2nd highest of 9, against a peer median of -37.9%.
  • Total equity amounts to 122.3% of total assets for AGEN, versus a peer median of 68.6%.
AGEN Competitors Peer median
Total Equity for AGEN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SEERSeer, Inc.Mar 2026$241.48M -22.4%-16.6%88.7%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$182.68M -38.2%-20.7%72.2%
FATEFate Therapeutics, Inc.Mar 2026$179.71M -37.7%-24.6%63.1%
PLRXPliant Therapeutics, Inc.Mar 2026$165.17M -35.8%-16.7%81.5%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$87.48M -43.8%-28.0%65.5%
HURATuHURA Biosciences, Inc.Mar 2026$23.19M +135.3%+19.4%78.1%
TTRXTurn Therapeutics Inc.Mar 2026$6.12M ——32.8%
INOInovio Pharmaceuticals, Inc.Mar 2026$6.07M -88.2%-52.3%12.2%
IRDOpus Genetics, Inc.Mar 2026-$45.84M -1003.5%-30.8%68.6%
AGENAgenus Inc.Mar 2026-$227.98M +29.3%—122.3%
Peer median (excluding AGEN) $87.48M-37.9%-22.7%68.6%

Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents291.93M178.67M76.11M40.44M3M
Short-term Investments14.99M14.68M000
Net Receivables1.52M2.74M25.84M407K1.83M
Inventory20.36M13.83M000
Other Current Assets(17.19M)(10.64M)2.37M2.42M128.61M
Total Current Assets331.97M213.12M112.42M45.57M133.44M
Property, Plant & Equipment (Net)91.08M164.29M163.03M147.4M24.25M
Goodwill24.88M25.47M24.72M24.09M24.09M
Intangible Assets8.49M6.23M4.41M3.38M3.04M
Long-term Investments003.22M4.64M42.73M
Tax Assets(2.67M)(2.67M)000
Other Non-current Assets12.21M7.12M6.11M1.19M(742K)
Total Non-current Assets133.98M200.43M201.5M180.7M93.36M
Total Assets465.96M413.56M313.91M226.27M226.8M
Account Payables30.49M40.94M61.45M61.47M82.99M
Short-term Debt728K575K146K2.7M155.11M
Tax Payables00000
Deferred Revenue12.43M12.27M18K31K1.14M
Other Current Liabilities75.66M101.49M141.21M121.85M83.11M
Total Current Liabilities156.94M188.95M255.9M221.4M323.49M
Long-term Debt12.82M12.58M12.77M30.47M169.66M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)11.2M1.14M1.14M1.14M1.14M
Other Non-current Liabilities194.97M202.45M125.26M225.13M242K
Total Non-current Liabilities261.11M279.51M206.4M311.29M181.17M
Total Liabilities418.05M468.46M462.3M532.7M504.66M
Common Stock2.57M3.06M3.94M236K353K
Retained Earnings(1.49B)(1.71B)(1.96B)(2.18B)(2.18B)
Accumulated OCI1.49M915K(955K)(1.4M)(439K)
Other Stockholders Equity00000
Minority Interest13.47M6.38M11.95M19.96M(6.75M)
Total Equity47.91M(54.9M)(148.38M)(306.42M)(277.86M)
Total Debt58.29M78.43M93.19M94.87M334.9M
Net Debt(233.64M)(100.25M)17.08M54.43M331.9M

Agenus Inc.

NASDAQ:AGEN

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.